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LETTER TO THE EDITOR
Fanconi Syndrome Associated with Valporic Acid:  
A Case Report 
 
 
Dear Editor, 
Fanconi syndrome is the most common cause of 
proximal renal tubular acidosis (RTA) in children and 
is characterized by hypophosphatemia due to phos-
phaturia, renal glucosuria (glucosuria with a normal 
plasma glucose concentration), aminoaciduria, and 
normal anion gap metabolic acidosis. Muscle weak-
ness is one of the Fanconi syndrome manifestations.
1,2 
Valporic acid (VPA) is an anti-epileptic drug 
widely used to treat partial and generalized seizures 
especially in children. Fanconi syndrome is a rare 
side effect in children during long-term VPA treat-
ment.
3,4 Herein, we reported a 14-year-old Iranian boy 
with progressive muscle weakness. He was diagnosed 
as a case of Fanconi syndrome secondary to VPA 
administration and showed dramatic response to 
treatment by carnitine supplement. 
The 14-year-old Iranian boy was referred to Mofid 
Children’s Hospital because of progressive muscle 
weakness. He was treated with VPA for 2 years due 
to his seizures attacks. With the exception of epilep-
sy, he was a healthy and active boy with normal de-
velopment and no relevant findings in his past medi-
cal history. Almost one year after he was started on 
VPA, he developed progressive muscle weakness 
with  myalgia and gradually he became unable to 
walk. On physical examination, muscle atrophy was 
detected and his proximal and distal muscle strength 
in both upper and lower limbs decreased. His Labora-
tory findings were as follows: 
Metabolic acidosis (VBG=pH 7.14, PCo2  =  41.9 
mmHg, serum bicarbonate=12.3 mmol/L), hypophos-
phatemia (p=3.2 mg/dL), hypokalemia (k=2.47 
mEq/dL) with normal calcium (9.2 mg/dL). The patient 
also had proteinuria (1+), glucosuria (1+) and his urine 
pH was 6, which were compatible with Fanconi syn-
drome. Blood urine nitrogen and creatinine levels were 
3 mg/dL and 0.9 mg/dL respectively. His parathormone 
hormone level was normal. Random sample of urine 
showed urine phosphorous of 131.4 mg/dL, urine calci-
um=186 mg/dL, and urine cratinine=29 mg/dL.  
Kidney ultrasound revealed hyperechogenicity in 
both kidneys and his muscle biopsy was highly com-
patible with mitochondriopathies or carnitine defi-
ciency. Because VPA appears to be the first suspicion 
for renal involvement, it stopped and carnitine was 
administered. Within 3 months, the muscle weakness 
improved and his kidney function recovered. People 
treated with VPA experienced some side effects; 
however, it is widely used as an effective anti-
epileptic drug. One of the important side effects of 
VPA is acquired type of Fanconi syndrome.  
A PubMed-based review of the literature revealed 
that Fanconi syndrome was a rare side effect in chil-
dren during VPA treatment. However, the detailed 
clinical characteristics of this disease remained un-
clear.
5 On the other hand, prolonged treatment with 
VPA enhanced renal losses of carnitine esters, lowers 
serum carnitine level, and resulted in secondary car-
nitine deficiency.
6 Secondary carnitine deficiency was 
described with some disorders including Fanconi 
syndrome and VPA therapy.
6,7 
Herein, we presented a 14-year-old Iranian boy that 
his physical examination and laboratory data were com-
patible with Fanconi syndrome. Considering 2 years 
history of VPA consumption, there was a probability of 
“VPA induced Fanconi syndrome”. Therefore, VPA 
was discontinued. Since carnitine deficiency has been 
seen after long term VPA therapy, L carnitine started for 
our patient.
8 His response was dramatic and all of his 
symptoms resolved within 6 months. 
Up to now there are 13 cases reported as “VPA 
induced Fanconi syndrome'”. A comprehensive re-
view of these cases, in 2010 by Endo et al.,
9 brought 
beneficial points. The average age of patients was 8.2 
years, the duration of VPA administration was 
6.4±3.4 months and almost all of the 13 patients were 
severely disabled, bed ridden, and fed through a gas-
trostomy tube. VPA was discontinued and urinary 
abnormalities disappeared within 3.8±2.7 months. All 
patients had favorable renal outcome.
10  
In contrast to this review article, our patients were 
mentally and developmentally healthy and VPA was 
started due to recent attacks of seizure. Similar to 
other cases, marked clinical improvement was ob-
served after cessation of VPA therapy but there was a 
unique point knowing that carnitine deficiency as a 
following sequence of VPA therapy, L Carnitin was 
started. The astounding response confirmed our find-
ing. So we can conclude that clinician should be Fanconi syndrome 
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aware of Fanconi syndrome as a result of prolonged 
VPA administration, although it is uncommon. 
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